FOLLOW-UP OF PATIENTS WITH COVID-19. (TeleRea'nCo)

TeleRea'nCo : FOLLOW-UP OF PATIENTS WITH COVID-19.

Some patients admitted to intensive care for a severe form of COVID-19 could have respiratory, cardiac, renal and neurological sequelae in the medium or long term.

The results of this research will allow an improvement in the understanding and management of patients in the medium and long term.

Study Overview

• Status: Withdrawn
• Conditions: Patient Admitted to Intensive Care Unit for COVID-19
• Intervention / Treatment: Other: Follow-up of patients with COVID-19

• Study Type: Observational

Contacts and Locations

Study Locations

• France
  • Strasbourg, France, 67091
    • Hôpitaux Universitaires de Strasbourg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patient admitted to intensive care unit for COVID-19.

Description

Inclusion Criteria:

• Patient admitted to intensive care unit for COVID-19
• Adult patient ≥ 18 years old
• Subject having expressed his non-opposition to the research
• Subject affiliated to a social health insurance protection scheme or beneficiary of such a scheme

Exclusion Criteria:

• Subject under safeguard of justice
• Patient under guardianship or curatorship

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patient admitted to intensive care unit for COVID-19	Other: Follow-up of patients with COVID-19; The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected. The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The presence of respiratory, renal, cardiac, motor, neurological, and psychological sequelae will be assessed by specialist doctors during the 12 months following the patient's discharge from intensive care.	The primary endpoint will be measured during 12 months following the patient's discharge from intensive care.

Secondary Outcome Measures

Outcome Measure	Time Frame
1) The sequelae by type of impairment will be assessed by specialist doctors at 3, 6 and 12 months	At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion
2) Number of re-hospitalizations at 3, 6 and 12 months	At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion
3) Date of death	Date of death will be collected from inclusion to M12 (12 months after patient inclusion)
4.1) Quality of life score (SF-36 questionnaire) at 3, 6 and 12 months	At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion
4.2) The Pittsburgh sleep quality index (PSQI questionnaire) at 3, 6 and 12 months	At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion
5) Cost of health expenditure	The cost of health expenditure will be collected from inclusion to M12 (12 months after patient inclusion)

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France

Study record dates

Study Major Dates

• Study Start (Actual): September 15, 2020
• Primary Completion (Actual): October 17, 2023
• Study Completion (Actual): October 17, 2023

Study Registration Dates

• First Submitted: October 26, 2020
• First Submitted That Met QC Criteria: October 29, 2020
• First Posted (Actual): October 30, 2020

Study Record Updates

• Last Update Posted (Estimated): September 16, 2025
• Last Update Submitted That Met QC Criteria: September 9, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: TeleRea'nCo; 7883 (Other Identifier: Hôpitaux Universitaires de Strasborug)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No